EA015078B1 - Preparation and method of prophylaxis and correction of pathological condition in animals - Google Patents

Abstract

The invention relates to preparations and methods of prophylaxis and treatment of hypoavitaminosis, normalization of metabolism, increase of organism resistance, at intoxication of agricultural and domestic animals the invention can be used in veterinary. The preparation and the method for use thereof provides more effective prophylaxis and treatment of animals. The preparation comprises the following substances: L-arginine monohydrochloride, L-lysine monohydrochloride, L-histidine monohydrochloride, L-isoleucine, L-leucine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-glutamin, L-valine, L-turrosine, L-cystine monochloride, L-serine, glycine, L-alpha-alanine, L-proline, L-aspartic acid, L-oxyproline, L-glutamic acid, cystein monohydrochloride choline chloride, folic acid, calcium pantothenate, thyamine hydrochloride, nicotinic acid, pyridoxal monohydrochloride, riboflavin, nicotinamide, D-biotin, myo-inositol, pyridoxine hydrochloride, calciferol, ascorbic acid, p-amino benzoic acid, glucose and also the following inorganic salts: sodium chloride, potassium chloride, monoeubstituted potassium phosphate, twice-substituted sodium phosphate, 6-aquatic sodium chloride, 6-aquatic magnesium chloride, 7-aguatic magnesium sulfate, 9-aquatic iron nitrate, 3-aquatic acetous sodium. The method for prophylaxis and correction of pathological conditions of animals is carried out by injection of the claimed preparation into animal's organism for prophylaxis twice a week during one month dosed 1.5-2.0 ml per 10 kg of animal's weight, for treatment dosed 3.0-5.0 ml per 1o kg of animal's weight twice a week during 3-5 days, at intoxications caused by poisoning by synthetic and/or food poisons tenfold dose compared to that of treatment dose.

Description

The invention relates to preparations and methods for the prophylaxis and treatment of hypoavitaminosis, normalization of metabolism, increase of body resistance, intoxication of farm and domestic animals and can be used in veterinary medicine.

In veterinary practice, animals often have symptoms of deficiency of a number of vitamins, which is facilitated by unbalanced and inadequate feeding, indigestion, exposure to various stresses, as well as factors generated by high-tech animal breeding. For the prevention of vitamin deficiencies, it is necessary to use vitamin preparations that regulate metabolic processes, as well as amino acids, which serve as a building material for protein molecules. Amino acids, being not only structural elements of proteins and other endogenous compounds, are of great functional importance. It is important to take amino acids with cofactors, which are usually vitamins, mineral salts and other nutrients that help amino acids during metabolic processes in animals. Preparations containing synthetic amino acids, fat-soluble and water-soluble vitamins, salts of trace elements are widely used as medicines for animals that affect the state of metabolism in the body and non-specific resistance factors.

A known composition of amino acids with trace elements and calcium, having antitumor, antidepressant and anticancer activity (RF patent No. 2151596, IPC A61K 31/197, publ. 06/26/2000). The composition contains ten natural amino acids with four trace elements and calcium.

However, this tool does not have sufficient preventive and therapeutic properties in the treatment of hypoavitaminosis, normalization of metabolism, to increase the resistance of the body, for detoxification in case of poisoning with food and synthetic poisons.

A known tool to increase the overall health of the body and stimulate metabolic processes, containing placenta extract for injection, sodium nucleinate and as a source of vitamins and amino acids - nutrient medium for cell cultures 199 (RF patent No. 2203073, IPC A61K 31/00, publ. 20.10. 2002).

This tool is effective against a number of pathological conditions of animals, however, when it is used, there is a danger of allergic reactions to placenta components that are alien to the animal organism and are introduced into the preparation.

A known drug used in the treatment of toxic infections to increase the body's resistance (RF patent No. 21689900, IPC A61K 31/195, publ. 06/20/2000). In this preparation, a culture medium for cell cultures 199 is used as a medicine. The composition of the culture medium for cell cultures includes amino acids, vitamins, coenzymes, sources of lipids (cholesterol, tween 80) and carbohydrates (glucose, Ό-ribose, 2-deoxy-E β-ribose, sodium acetate), as well as nucleic acid precursors [1].

However, such a composition of the medium is necessary for cell growth in the ίη νίίτο culture, since the rate of synthesis of some amino acids in an isolated cell is extremely insufficient to ensure intensive growth, which is a feature of cell cultures. The needs of cells in culture depend on many factors (including the concentration of the cells themselves, their origin, the concentration of substances necessary for cell growth on the glass surface, the concentration of hydrogen ions in the environment, etc.) and significantly differ from the needs of cells in living organism [2]. It is known that L-glutamine contained in the nutrient medium partially passes into pyrrolidone carboxylic acid during the first three months of storage, and a high content of aspartic acid in the medium can lead to brain disorders in young experimental animals [3, 4]. At the same time, ATP, which is part of medium 199, is a drug with a very fast decomposition period (about 30 s) and its administration intramuscularly is not very effective. In addition, the use of the composition of the nutrient medium necessary for cell growth in the ίη νίίτο culture significantly increases the cost of the drug when used as a medicine ίη νίνο.

The closest analogue (prototype) of the drug is a drug in the form of an aqueous solution containing L-lysine hydrochloride in an amount of 20-25 mg / ml, O-methionine in an amount of 20-25 mg / ml, glycine in an amount of 20-25 mg / ml, vitamin B ₈ in an amount of 10-15 mg / ml, vitamin B ₁₂ in an amount of 0.150.16 mg / ml, provitamin B3 in an amount of 15-20 mg / ml, vitamin H in an amount of 0.010-0.015 mg / ml, as well as ammonium citrate iron in an amount of 1.7-1.8 mg / ml in terms of Fe ion (+3), cobalt sulfate in an amount of 0.095-0.100 mg / ml in terms of Co ion (+2), copper sulfate in an amount of 0.028-0.029 mg / ml in terms of on ion Cu (+2) described in the patent of the Russian Federation No. 2343906, IPC A61K 31/00, publ. January 20, 2009

The closest analogue (prototype) of the method is a method for the correction and prevention of pathological conditions of animals, protected (RF patent No. 2343906, IPC АКК 31/00, published on January 20, 2009). This method proposes the correction and prevention of pathological conditions of animals by introducing into the body of an animal a preparation including amino acid and vitamin complexes containing additional physiologically acceptable salts of Fe (3+), Co (2+), Cu (2+) in the form of injections once in 2-4 days with a total number of injections of not more than 10. The drug is administered to animals weighing up to 3 kg at a dose of 0.1 ml, animals weighing from 3 to 5 kg at a dose of 0.25 ml, animals with

- 1 015078 weighing over 5 to 15 kg at a dose of 0.5 ml, and for animals with a mass of over 15 to 45 kg at a dose of 1 ml. The drug is administered to horses, cattle and pigs at a dose of 1 ml per 45 kg of live weight.

However, the prototype drug and the method of its use provide insufficiently effective prevention and correction of the pathological condition of the animal organism, for example, in the treatment of hypoavitaminosis, normalization of metabolism, and detoxification of the animal organism during food poisoning.

The technical result of the proposed drug and its use is to provide more effective prophylaxis and treatment of animals, for example, with hypoavitaminosis, normalization of metabolism, increased body resistance and detoxification during food poisoning of the animal organism.

The specified technical result is achieved by using a preparation for the prevention and correction of pathological conditions of animals containing the following active substances: Larginine monohydrochloride in an amount of 48-72 mg / L, L-lysine monohydrochloride in an amount of 48-72 mg / L, L-histidine monohydrochloride in an amount of 13 , 8-20.8 mg / l, L-isoleucine in an amount of 13.8-20.8 mg / L, L-leucine in an amount of 41.6-62.4 mg / L, L-methionine in an amount of 10.4-15 6 mg / l, L-phenylalanine in an amount of 17.2-25.8 mg / L, L-threonine in an amount of 20.8-31.2 mg / L, L-tryptophan in an amount of 7.9-10.3 mg / L, glutamine an amount of 68.8-103.2 mg / l, L-valine in an amount of 17.2-25.8 mg / L, L-tyrosine in an amount of 27.741.5 mg / L, L-cystine monochloride in an amount of 17.9- 26.9 mg / l, L-serine in an amount of 17.2-25.8 mg / L, glycine in an amount of 34.4-54.6 mg / L, L-alpha-alanine in an amount of 17.2-25, 8 mg / L, L-proline in an amount of 25.6-38.4 mg / L, L-aspartic acid in an amount of 18.0-30.0 mg / L, L-hydroxyproline in an amount of 7.9-10.3 mg / L, L-glutamic acid in an amount of 48-72 mg / L, L-cysteine monohydrochloride in an amount of 0.12-0.70 mg / L, choline chloride in an amount of 0.4-3.0 mg / L, folic acid the amount of 0.01-0.09 mg / l, calcium pantothenate in quantity 0.01-0.09 mg / L, thiamine hydrochloride in an amount of 0.01-0.09 mg / L, nicotinic acid in an amount of 0.03-0.22 mg / L, pyridoxal monohydrochloride in an amount of 0.03- 0.22 mg / l, riboflavin in an amount of 0.012-0.09 mg / l, nicotinamide in an amount of 0.03-0.22 mg / l, y-biotin in an amount of 0.01-0.09 mg / l, myoinositol in an amount of 0.06-0.45 mg / l, pyridoxine hydrochloride in an amount of 0.03-0.22 mg / l, calciferol in an amount of 0.01-0.09 mg / l, ascorbic acid in an amount of 0.06- 0.45 mg / l, para-aminobenzoic acid in an amount of 0.06-0.45 mg / l, glucose in an amount of 800-1200 mg / l, as well as the following inorganic and: sodium chloride in an amount of 7.2-8.8 g / l, potassium chloride in an amount of 360-440 mg / l, potassium phosphoric acid monosubstituted in an amount of 54-66 mg / l, sodium phosphoric acid disubstituted 12-water in the amount of 13.5-16.5 mg / l, calcium chloride 6-water in the amount of 24.8-30.4 mg / l, magnesium chloride 6-water in the amount of 9.9-11.6 mg / l, magnesium 7-hydrous sulfate in an amount of 9.011.0 mg / L, 9-hydrous iron nitrate in an amount of 0.65-0.79 mg / L, 3-aqueous sodium acetate in an amount of 7.1-8.7 mg / L.

The specified technical result is also achieved by the fact that in the method for the prevention and correction of pathological conditions of animals by injecting an animal preparation in the form of an aqueous solution according to the invention, the preparation according to claim 1 is used as a preparation, which is administered to animals intramuscularly or subcutaneously with prophylactic the goal 2 times a week for a month in doses of 1.5-2.0 ml per 10 kg of body weight, with a therapeutic purpose in a dose of 3.0-5.0 ml per 10 kg of body weight 2 times a day for 3- 5 days, with intoxication s due to the poisoning of synthetic and / or food poisons - tenfold in therapeutic dose. Moreover, if the dose of the drug exceeds 20 ml, then it is administered in several places.

Obtaining the specified technical result is achieved by the development of optimal qualitative and quantitative compositions and methods for preparing aqueous solutions of amino acids, vitamins, micro and macro elements, glucose, normalizing metabolic processes in the animal’s body, as well as in the proposed scheme for the use of the drug.

The experimentally established doses of the drug provide its effectiveness for the prevention and treatment of pathological conditions of animals associated with hypoavitaminosis, to normalize metabolism and increase body resistance, in case of intoxication of farm and domestic animals.

In the preparation of the prototype, only three essential amino acids are used - lysine, methionine and glycine in equal proportions, 4 vitamins (B ₈ , B ₁₂ , B ₃ and vitamin H) and trace elements (iron, cobalt and copper ions), which is not enough to obtain technical result in the claimed technical solution: more effective prevention and treatment of hypoavitaminosis, normalization of metabolism, to increase the body's resistance, for detoxification in food poisoning.

Methionine in the preparation of the prototype is clearly in excess (1.5-2 times higher than the required norm), and lysine and glycine are deficient. Despite the fact that methionine is used in the body for the synthesis of choline, it affects the metabolism of fats and phosphatides in the liver, normalizing its condition, excessive, unbalanced intake of methionine can lead to its conversion to mercaptan, which in large quantities leads to the manifestation of signs of hepatic encephalopathy.

The claimed preparation contains 21 amino acids, including all essential amino acids. Compared with the prototype, additional amino acids such as b-arginine, b-histidine, b

- 20155078 isoleucine, b-leucine, b-phenylalanine, b-threonine, b-tryptophan, b-glutamine, b-valine, b-tyrosine, b-cystine, b-cysteine, b-serine, b-alpha-alanine, b proline. Inadequate intake of essential amino acids into the body, as well as a violation of their quantitative ratio, leads to disruption of protein synthesis. Deficiency of even one essential amino acid can lead to a change in the structure of any enzyme, which, in turn, will lead to disruption of individual metabolic links.

It is important that amino acids enter the body along with cofactors. The action of amino acids involves complex metabolic pathways that require different cofactors and other amino acids. Cofactors, which are usually vitamins and other substances (in this application, L-aspartic acid, folic acid, calcium pantothenate, nicotinic acid, pyridoxal monohydrochloride, riboflavin, nicotinamide, би-biotin, myoinositol, calciferol, para-aminobenzoic acid) in the application, it is sodium chloride, potassium chloride, potassium phosphoric acid monosubstituted, sodium phosphoric acid disubstituted 12-water, calcium chloride 6-water, magnesium chloride 6-water, magnesium sulfate 7-water, iron nitrate 9 -hydrous, sodium acetic acid 3-aqueous) and other substances that help amino acids during metabolic processes in animals.

In a healthy body, an amino acid such as cystine is synthesized in sufficient quantities from methionine. However, the lack of enzymes observed in metabolic disorders, various stress conditions, intestinal diseases, poisoning, limits the various stages of metabolism associated with the transfer of sulfo groups, leads to a decrease in the ability to synthesize cysteine to fully satisfy the need for it. At the same time, cystine and cysteine are necessary for detoxification processes. Cysteine plays an important role in the formation of skin tissues and mucous membranes. It is one of the most powerful antioxidants, is the precursor of glutathione - a substance that has a protective effect on liver and brain cells from damage to certain toxic substances. This amino acid also speeds up fat burning and muscle formation. L-cystine has the ability to destroy mucus in the respiratory tract, accelerates the healing process in diseases of the respiratory system and plays an important role in the activation of leukocytes and lymphocytes.

The body also needs other essential amino acids. For example, isoleucine - one of the essential amino acids necessary for the synthesis of hemoglobin, together with b-leucine stimulates the growth of muscle tissue; threonine - helps maintain normal protein metabolism in the body, is important for the synthesis of collagen and elastin, helps the liver and participates in the metabolism of fats in combination with aspartic acid and methionine. In addition, threonine stimulates the immune system, as it promotes the production of antibodies. Valine is necessary for metabolism in the muscles, restoration of damaged tissues and to maintain a normal nitrogen metabolism in the body. L-glutamine helps to strengthen the immune system, participates in the synthesis of other amino acids, participates together with L-alpha-alanine in the detoxification of the body, removes ammonia. L-tyrosine has a stress-protective effect. L-serine is an important participant in the formation of cysteine, helps to eliminate pain, improves the functioning of the liver together with L-histidine. L-arginine promotes the synthesis of growth hormones and other hormones, has a detoxifying effect, improves the rheological properties of blood. L-phenylalanine improves digestion, stimulates the production of gastric juice. L-tryptophan has a calming effect under stress, improves sleep. L-proline improves the structure of the skin and restores the mucous membranes of the body.

Since the process of protein synthesis in the body is constant, in the case when at least one irreplaceable amino acid is absent, their formation is suspended, and due to the impossibility of implementing many biochemical processes, this leads to the development of various diseases. In addition, under certain conditions (for various diseases or a deficiency in the protein diet), the synthesis of amino acids in the body decreases sharply. With the disease, conditionally essential amino acids can also become indispensable. This is especially true for aromatic amino acids phenylalanine and tyrosine, as well as sulfur-containing amino acids, such as, for example, cysteine.

Analysis and systematization of literature data and the results of our own studies confirm that the components included in our preparation provide a well-balanced amount of essential and non-essential amino acids that is sufficient to maintain the physiological level of amino acids in the blood plasma, and the ratio of the concentrations of individual amino acids is not violated.

The use of the claimed drug leads to the rapid restoration of impaired homeostasis, normal metabolism, stimulates the body's defenses necessary for its functioning. The proposed drug, containing all interchangeable and essential amino acids necessary for protein biosynthesis in the body, vitamins and trace elements, is recommended to ensure the normal growth and development of animals, treatment and prevention of diseases of various etiologies as a general strengthening agent for farm and domestic animals with anemia, hypoavitaminosis, pregnancy toxicosis, bronchitis, pneumonia, etc.

The advantage of the proposed drug over the prototype and other analogues is

- 3 015078 balance of amino acid composition, which increases the degree of assimilation of the drug and reduces the risk of reactions to its introduction. The action of the proposed drug is due to the effects of vitamins and amino acids included in its composition, the drug prevents the occurrence of vitamin deficiency, normalizes carbohydrate, protein and fat metabolism, stimulates the body's immune defense.

Due to the qualitative and quantitative composition of the drug used in the proposed method and the developed scheme for its use in experimentally established doses, the invention meets the criterion of inventive step.

The technology of obtaining the drug.

Inorganic salts are dissolved in 100 l of purified water (pH from 5.0 to 7.0 units): sodium chloride in an amount of 7.2-8.8 g / l, potassium chloride in an amount of 360-440 mg / l, potassium phosphorus - mono-substituted acid in an amount of 54-66 mg / l, sodium phosphoric acid disubstituted 12-aqueous in an amount of 13.5-16.5 mg / l, calcium chloride 6-aqueous in an amount of 24.8-30.4 mg / l Magnesium chloride 6-aqueous in an amount of 9.9-11.6 mg / L, Magnesium sulfate 7-aqueous in an amount of 9.0-11.0 mg / L, Iron nitrate 9-aqueous in an amount of 0.65-0, 79 mg / l, sodium acetate 3-aqueous in an amount of 7.1-8.7 mg / l. Dissolution is carried out with stirring for at least 5-7 minutes.

Then amino acids and vitamins are subsequently dissolved: L-arginine monohydrochloride in an amount of 48-72 mg / L, L-lysine monohydrochloride in an amount of 48-72 mg / L, L-histidine monohydrochloride in an amount of 13.8-20.8 mg / L, B-isoleucine in an amount of 13.8-20.8 mg / l, b-leucine in an amount of 41.6-62.4 mg / l, b-methionine in an amount of 10.4-15.6 mg / l, b- phenylalanine in an amount of 17.2-25.8 mg / l, L-threonine in an amount of 20.8-31.2 mg / L, L-tryptophan in an amount of 7.9-10.3 mg / L, L-glutamine the amount of 68.8-103.2 mg / l, L-valine in the amount of 17.2-25.8 mg / L, L-tyrosine in the amount of 27.7-41.5 mg / L, L-cystine monochloride in the amount one 7.9-26.9 mg / l, L-serine in an amount of 17.2-25.8 mg / L, glycine in an amount of 34.4-54.6 mg / L, Alfa-alanine in an amount of 17.2- 25.8 mg / l, L-proline in an amount of 25.6-38.4 mg / L, L-aspartic acid in an amount of 18.0-30.0 mg / L, L-hydroxyproline in an amount of 7.9-10 , 3 mg / L, L-glutamic acid in an amount of 48-72 mg / L, L-cysteine monohydrochloride in an amount of 0.12-0.70 mg / L, choline chloride in an amount of 0.4-3.0 mg / L folic acid in an amount of 0.01-0.09 mg / l, calcium pantothenate in an amount of 0.01-0.09 mg / l, thiamine hydrochloride in an amount of 0.01-0.09 mg / l, nicotinic acid in an amount 0.03-0.22 mg / l, pyridoxal mon hydrochloride in an amount of 0.03-0.22 mg / l, riboflavin in an amount of 0.012-0.09 mg / l, nicotinamide in an amount of 0.03-0.22 mg / l, Ό-biotin in an amount of 0.01-0 , 09 mg / l, myoinositol in an amount of 0.06-0.45 mg / l, pyridoxine hydrochloride in an amount of 0.03-0.22 mg / l, calciferol in an amount of 0.010.09 mg / l, ascorbic acid in an amount of 0 , 06-0.45 mg / l, para-aminobenzoic acid in an amount of 0.06-0.45 mg / l. L-cystine is dissolved in a 0.1 mol / L hydrochloric acid solution before loading into the reactor.

Then, glucose in the amount of 800-1200 mg / l, phenol red water-soluble in the amount of 18-22 mg / l are dissolved and a solution of sodium carbonate is added at the rate of 540-660 mg / l. The volume of the drug solution is adjusted to 100 l with purified water. Set the indicator of the concentration of hydrogen ions (pH) equal to 7.1-7.5, and then subjected to the prepared solution of sterilizing filtration.

The following are examples 1 and 2 of the composition of the drug.

Example 1. The composition of the drug for the prevention of diseases.

L-arginine monohydrochloride in an amount of 48 mg / L, L-lysine monohydrochloride in an amount of 48 mg / L, L-histidine monohydrochloride in an amount of 13.8 mg / L, L-isoleucine in an amount of 13.8 mg / L, L-leucine in an amount of 41.6 mg / l, L-methionine in an amount of 10.4 mg / L, L-phenylalanine in an amount of 17.2 mg / L, L-threonine in an amount of 20.8 mg / L, L-tryptophan in an amount of 7, 9 mg / L, L-glutamine in an amount of 68.8 mg / L, L-valine in an amount of 17.2 mg / L, L-tyrosine in an amount of 27.7 mg / L, L-cystine monochloride in an amount of 17.9 mg / l, L-serine in an amount of 17.2 mg / l, glycine in an amount of 34.4 mg / l, L-alpha-alanine in an amount of 1 7.2 mg / l, L-proline in an amount of 25.6 mg / L, L-aspartic acid in an amount of 18.0 mg / L, L-hydroxyproline in an amount of 7.9 mg / L, L-glutamic acid in an amount 48 mg / l, L-cysteine monohydrochloride in an amount of 0.12 mg / l, choline chloride in an amount of 0.4 mg / l, folic acid in an amount of 0.01 mg / l, calcium pantothenate in an amount of 0.01 mg / l , thiamine hydrochloride in an amount of 0.01 mg / l, nicotinic acid in an amount of 0.03 mg / l, pyridoxal monohydrochloride in an amount of 0.03 mg / l, riboflavin in an amount of 0.012 mg / l, nicotinamide in an amount of 0.03 mg / l, Ό-biotin in an amount of 0.01 mg / , myoinositol in an amount of 0.06 mg / l, pyridoxine hydrochloride in an amount of 0.03 mg / l, calciferol in an amount of 0.01 mg / l, ascorbic acid in an amount of 0.06 mg / l, para-aminobenzoic acid in an amount of 0.06 mg / l, glucose in the amount of 800 mg / l, sodium chloride in the amount of 7.2 g / l, potassium chloride in the amount of 360 mg / l, potassium phosphoric acid monosubstituted in the amount of 54 mg / l, sodium phosphoric acid disubstituted 12 water in an amount of 13.5 mg / l, calcium chloride 6-water in an amount of 24.8 mg / l, magnesium chloride 6-water in an amount of 9.9 mg / l, magnesium sulfate 7-water first in an amount of 9.0 mg / L iron nitrate 9-water in an amount of 0.65 mg / l, sodium acetate 3-aqueous in an amount of 7.1 mg / l.

Example 2. The composition of the drug for the correction of pathological conditions.

L-arginine monohydrochloride in an amount of 72 mg / L, L-lysine monohydrochloride in an amount of 72 mg / L, L-histidine monohydrochloride in an amount of 20.8 mg / L, L-isoleucine in an amount of 20.8 mg / L, L-leucine in

- 4 015078 in an amount of 62.4 mg / l, L-methionine in an amount of 15.6 mg / L, L-phenylalanine in an amount of 25.8 mg / L, L-threonine in an amount of 31.2 mg / L, L-tryptophan in an amount 10.3 mg / l, L-glutamine in an amount of 103.2 mg / L, L-valine in an amount of 25.8 mg / L, L-tyrosine in an amount of 41.5 mg / L, L-cystine monochloride in an amount of 26 , 9 mg / l, L-serine in an amount of 25.8 mg / L, glycine in an amount of 54.6 mg / L, L-alpha-alanine in an amount of 25.8 mg / L, L-proline in an amount of 38.4 mg / L, L-aspartic acid in an amount of 30.0 mg / L, Loxyproline in an amount of 10.3 mg / L, L-glutamic acid in an amount of 72 mg / L, L-cysteine monogy drochloride in an amount of 0.70 mg / l, choline chloride in an amount of 3.0 mg / l, folic acid in an amount of 0.09 mg / l, calcium pantothenate in an amount of 0.09 mg / l, thiamine hydrochloride in an amount of 0.09 mg / l, nicotinic acid in an amount of 0.22 mg / l, pyridoxal monohydrochloride in an amount of 0.22 mg / l, riboflavin in an amount of 0.09 mg / l, nicotinamide in an amount of 0.22 mg / l, Ό-biotin 0.09 mg / L, myoinositol in an amount of 0.45 mg / L, pyridoxine hydrochloride in an amount of 0.22 mg / L, calciferol in an amount of 0.09 mg / L, ascorbic acid in an amount of 0.45 mg / L, para-aminobenzoic acid in an amount of 0.45 mg / l, glucose in an amount of 1200 mg / l, sodium chloride in an amount of 8.8 g / l, potassium chloride in an amount of 440 mg / l, potassium phosphoric acid monosubstituted in an amount of 66 mg / l, sodium phosphate disubstituted 12-aqueous in an amount of 16.5 mg / l, calcium chloride 6-aqueous in an amount of 30.4 mg / l, magnesium chloride 6-aqueous in an amount of 11.6 mg / l, magnesium sulfate 7-aqueous in an amount 11.0 mg / l, iron nitrate 9-aqueous in an amount of 0.79 mg / l, sodium acetic acid 3-aqueous in an amount of 8.7 mg / l.

Example 3. Schemes for the use of drug formulations.

The drug according to example 1 is administered to animals in the form of injections intramuscularly or subcutaneously for prophylactic purposes 2 times a week for a month in doses of 1.5-2.0 ml per 10 kg of body weight (if the dose exceeds 20 ml, then the drug is administered in several places )

The preparation according to example 2 is administered to animals in the form of injections intramuscularly or subcutaneously for therapeutic purposes at a dose of 3.0-5.0 ml per 10 kg of body weight 2 times a day for 3-5 days. In case of intoxication (poisoning with synthetic and food poisons) - in a ten-fold therapeutic dosage (if the dose exceeds 20 ml, then the drug is administered in several places).

Since the inventive method uses a multicomponent drug, a study was conducted of its acute toxicity, allergenic effect in laboratory animals, tolerance, subchronic toxicity.

Examples 4, 5, 6 confirm the absence of the toxic effect of the drug, confirm that the proposed drug does not have an allergenic effect, does not adversely affect the physiological state of the animal organism, biochemical blood parameters and does not cause macro- and microscopic changes on the part of internal organs.

The effectiveness of using the proposed method to ensure normal growth and development of animals, treatment and prevention of diseases of various etiologies as a general strengthening agent for farm and domestic animals with anemia, hypoavitaminosis, pregnancy toxicosis, patients with bronchopneumonia, dysbiosis and others was also confirmed (examples 7, 8, nine).

Example 4. Assessment of acute toxicity of the proposed drug.

Assessment of acute toxicity of the proposed drug was carried out on white rats of both sexes weighing 230-240 g. The drug was administered intragastrically in doses of 1.5; 2.5 and 3.5 ml (the third dose is maximum in volume of the stomach). The control group of animals was injected with distilled water. Observations were carried out for 14 days. From the side of the coat, mucous membranes and the condition of the auricles, no deviations were recorded. With macroscopy of the internal organs of animals, hemorrhages and inflammatory processes were not detected. The mucous membrane of the esophagus, stomach and intestines had no signs of pathology. Mass coefficients of the internal organs of experimental animals had no differences from the control. There were no cases of death of animals in any of the groups. The data obtained indicate the absence of the toxic effect of the proposed drug and make it possible to classify it as a 4th class — low-hazard substances (GOST 12.1.007-76), and it is not possible to establish a lethal dose.

In addition, the parameters of acute toxicity were determined by a single intramuscular injection in 56 white outbred rats of both sexes weighing 220-240 g. The animals were divided into 6 experimental and one control group of 8 animals each. The drug was administered at the rate of 650, 975, 1463, 2194, 3291, 4936 mg / kg, respectively, in groups.

The control animals were not injected with the drug. Observation of laboratory animals was conducted for 14 days. On the 15th day of the experiment, the animals were decanted (after euthanasia with ether) and an autopsy was performed. As a result of the autopsy in animals of all experimental groups, no pathological changes were revealed, which allows us to conclude that the proposed composition is safe. Additional tests of acute toxicity also did not allow to establish ΤΌ50 for the study drug, which allows it to be attributed to substances of hazard class 4 according to the hygienic classification GOST 12.1.007-76.

Example 5. The study of the allergenic effect was carried out on guinea pigs by skin.

- 5 015078 applications of the solution of the proposed composition taking into account body weight, rectal temperature, white blood cell count, specific white blood cell agglomeration (RSAL) reaction. As a result of the studies, it was found that when applying the drug in an amount of 1.0 and 2.0 ml / kg for 18 days, all the considered parameters were within the physiological norm, statistically significant changes in rectal temperature, white blood cell count, and also RSAL results between experimental and control groups were not observed. Thus, the proposed drug does not have an allergenic effect and can be prescribed to animals with the necessary frequency for prevention and treatment.

Example 6. The study of the tolerance of the proposed drug.

To assess the tolerability of the drug, 4 groups (3 experimental and 1 control) of piglets of 7 goals each were formed. For experimental groups, the drug was administered intramuscularly at the rate of 2.0 6.0 and 10 ml per 10 kg of live weight (conditionally therapeutic, 3- and 5-fold dose from conditionally therapeutic) for 20 days. It was established that during the experimental period, none of the applied doses of the drug had a negative effect on the body of piglets, on the biochemical parameters of blood of piglets of all groups, the death of animals was not observed either in the control or in the experimental groups. Moreover, over the study period, the average daily increase in piglets in the experimental groups exceeded the figures in the control group by 2.14; 4.52 and 4.03%, which indicates the safety of the drug and good bioavailability of the biologically active substances of the drug. The slaughter of piglets at the end of the experimental period and macroscopic studies of the intestines and internal organs confirmed the absence of pathological changes in the tissues and organs of animals that were injected with the highest doses of the drug.

The study of tolerance in calves was carried out on black-motley calves aged 2 to 10 days, of which 3 experimental and control groups of 5 calves were formed in each group. Animals in the experimental groups were selected on the basis of analogues taking into account age, weight and physiological condition. For experimental groups, the drug was administered intramuscularly at the rate of 2.0 6.0 and 10 ml per 10 kg of live weight (conditionally therapeutic, 3- and 5-fold dose from conditionally therapeutic) for 20 days. As a result of the studies, it was found that during the entire experimental period, none of the doses of the drug had a negative effect on the body of calves. Neither in the control nor in the experimental groups, the death of animals was not observed. During the study period, the average daily increase in calves in the experimental groups exceeded the indicators in the control group by 5.53, 8.93 and 3.82%, which indicates the safety of the drug and the good bioavailability of the biologically active substances of the drug. Studies on calf blood morphobiochemical parameters performed on the twentieth day of the drug showed that, on average, red blood cells increased by 0.13x10 ¹² / l, hemoglobin increased by 0.45 g /%, and the color indicator decreased by 0.01. The number of leukocytes increased by 0.34x10 ⁹ / l, ESR decreased by 0.36 mm. Such indicators may indicate normalization of body functions - increased phagocytic activity, improved respiratory activity of blood functions and increased body resistance.

Thus, the 20-day intramuscular injection of weaning pigs and calves of the proposed drug in doses of 2.0, 6, 0 and 10 ml per 10 kg of live weight does not adversely affect the physiological state of the animal organism, biochemical blood parameters and does not cause macro- and microscopic changes from the internal organs.

Examples 7-10 below show the results of the prevention and treatment of animals.

Example 7. Data on the prevention of diseases of pigs.

Tests of the effectiveness of the drug according to example 1 for prophylactic purposes was carried out on 54 pregnant sows, which were divided according to the principle of pair-analogues into 3 groups of 18 animals each. The first group - the control - was injected intramuscularly with sterile purified water. The second and third experimental groups were administered the drug at the rate of 1.5 and 2.0 ml per 10 kg of body weight 2 times a week for a month. The amount of the drug administered in one place did not exceed 15 ml. The research results are presented in table. 1. As can be seen from the table. 1, in the experimental groups, more viable piglets were born in sows than in the control by 5.7 and 12.3%, respectively. The live weight of one piglet at birth was also 0.03 and 0.07 kg more.

At the same time, the preparation had a positive effect on the subsequent growth of piglets: by the time of weaning, the average weight of the piglets in the control group was 7.33 kg, while in the experimental groups 8.15 and 8.27 kg. The introduction of the drug to sows made it possible to ensure a slightly greater safety of piglets by 8.7 and 24.1%, which can be explained by an improvement in the general physiological state of the body of sows. In the blood of sows, the number of red blood cells increased by 3.1-6.2%. The hemoglobin concentration also increased dose-dependently by 6.7 and 8.9%, respectively. In the content of leukocytes significant differences in groups were not observed. The total protein content increased in the second group by 5.4%, in the third - by 7.6%. More vitamin A was found in blood serum in the second group by 28.6, and in the third - by 36.4%. Studies have confirmed the positive effect of the proposed drug on the body of sows and newborn piglets.

- 6 015078

Piglets obtained from sows in the experiment were sown and continued to receive injections of the drug according to the treatment regimen, i.e. 3.0-5.0 ml per 10 kg of body weight 2 times a day for 5 days. Observations were carried out until the age of 90 days of piglets. A positive effect of the proposed drug on the meat productivity of piglets was noted. Animals from the experimental groups in terms of live weight gain exceeded the control by 7.4 and 9.6%. Hematological blood counts of the piglets receiving the drug (at the age of 90 days) are presented in table. 2, show a trend of improvement in blood hemoglobin, total protein, protein index, urea content. The data obtained indicate good bioavailability and digestibility by the animal organism of the proposed drug. The use of the proposed drug leads to a decrease in postnatal mortality and increased viability of the offspring.

Example 8. Data on the prevention of diseases of calves.

To test the effectiveness of the drug according to example 2 for prophylactic purposes, 28 calves from 1- to 1.5-month-old calves were selected on calves and 2 groups were formed (control and experimental) with 14 goals each. The first group was the control, the calves of the second experimental group were injected with the preparation according to example 2 at the rate of 1.5 and 2.0 ml per 10 kg of body weight 2 times a week for a month. The drug showed a positive effect on the dynamics of body weight and calf growth. From the table. Figure 3 shows that the average daily gain in live weight of calves in the experimental group (receiving intramuscular injections of the drug) exceeded the control by 5.1%. Feed costs per unit of growth were lower in the experimental group by 5.4% than in the control group. The safety in all groups at the end of the experiment was 100%. The injection of calves also contributed to an increase in their natural resistance, and therefore, in the experimental group, calves were much less likely to have respiratory and gastrointestinal diseases. Morphological and biochemical studies of calf blood were also performed (Tables 4, 5). The results presented in table 4 indicate that the concentration of red blood cells in calves in the experimental group at the end of the experiment was 10% higher than in the control. A significant increase in white blood cell count was observed. In the experimental group, the amount of hemoglobin increased by 15.3%, which indicates a positive effect of the drug. Biochemical studies of calf blood (Table 5) showed an increase in total protein in the blood serum of calves in the experimental group compared to the control group by 7.9%. The vitamin A content in the experimental group also exceeded the control by 17.7%. In addition, the level of ascorbic acid and vitamin E was increased in the blood serum. The above data indicate the effectiveness of the drug and the feasibility of its use to calves, since after using the proposed drug there are no external signs of vitamin deficiency, the content of vitamins A, E, C in the blood serum of calves increases.

Thus, tests of the proposed drug for prophylactic purposes on pigs and calves confirm that the proposed drug helps to increase the safety and productivity of animals, improve the clinical condition by optimizing the metabolic processes in the body associated with the content of amino acids, vitamins and minerals.

Example 9. Data on the treatment of calves of patients with bronchopneumonia.

To test the effectiveness of the drug according to example 2 for therapeutic purposes, the inventive method was used in the treatment of calves with bronchopneumonia. When making the diagnosis, the history, clinical studies, hematological and biochemical blood tests of the blood of sick calves were taken into account.

For the test, 20 heads of 3-month-old sick calves were selected, their average weight was 78 kg. The groups were formed according to the principle of analogues: 2 groups of 10 goals each. The conditions of feeding and feeding were identical. The animals of the experimental and control groups underwent a set of necessary therapeutic measures. In addition, the animals of the first group (control) received a drug used on the farm, trivitamin (1 ml of the drug contains vitamin A 15000ME, vitamin I 20,000 IU, vitamin E 10 mg), the calves of the second group were injected with the inventive preparation according to example 2 intramuscularly into the buttocks 3, 0-5.0 ml per 10 kg of body weight 2 times a day for 5 days. The results of therapeutic measures are presented in table. 6. The average daily gain in live weight in the experimental group of calves is higher than those in the control group by 2 times. At the same time, 100% of calves recovered in the experimental group, in contrast to the control group, in which the mortality rate was 20%. After treatment of sick calves, changes in hematological and biochemical parameters of blood were noted in both groups (Tables 7, 8). Blood was taken again after the clinical recovery of sick calves. As a result of laboratory studies, it was found that in the blood of calves of the first group, the hemoglobin content and the number of red blood cells increased. The number of leukocytes decreased to a physiological norm, there are no young forms of neutrophils. In the blood of calves of the experimental second group, an increase in the hemoglobin content and the number of red blood cells was noted. Changes in the leukocyte formula are similar to those in the first group. There have also been significant changes in the biochemical parameters of the blood of calves after their recovery. In recovered calves, an increase in the content of total protein, calcium, is noted. Moreover, changes in the hematological parameters of blood of calves after treatment in the experimental group are much better than in the control group. The same picture is observed in biochemical

- 7 015078 indicators, which indicates the therapeutic activity of the claimed drug for bronchopneumonia of calves.

When using the drug according to example 2 to calves from 15 days to 10 months in complex treatment for enteritis, gastroenteritis, calves showed improvement in general condition, appetite appeared, metabolic processes returned to normal, recovery processes were accelerated 2-3 times compared with calves, which the drug was not administered.

Example 10. Data on the treatment of dogs with food poisoning.

The inventive method was used in the treatment of dogs with diseases and critical conditions resulting from ingestion of initially toxic substances, as well as food products that become toxic as a result of improper storage, in order to restore impaired functions of organs and the whole organism.

To test the drug, 29 animals with clinical signs of enterocolitis were selected as complications of poisoning or intoxication, aged 13 to 18 months and body weight from 7.4 to 13.6 kg. All animals were housed in cages with 2 or 3 heads in each. Animals were divided into 3 groups according to the principle of analogues. The first group - 9 animals, control; the second group and the third group - 10 animals each, experimental. Animals 2 (with signs of enterocolitis) and 3 (in a state of food poisoning) of the experimental groups received a course of intramuscular injection of the drug according to example 2. The dose for injection for each animal of the 2nd group was determined in accordance with its weight based on 3.0 ml of the drug per 10 kg of body weight, and for animals of 3 groups at the rate of 30-50 ml per 10 kg of body weight, depending on the state of the body. The calculated amount of the drug was administered 2 times a day for 5 days. The animals of the control group were injected with a glucose solution.

Observation of the condition of the animals confirmed a more rapid decrease in the phenomena of intoxication in animals in the experimental groups, the manifestations of gastrointestinal dysfunction stopped faster, and the manifestations of weakness and exhaustion disappeared. Morpho-biochemical blood parameters of dogs also quickly reached the average standard level in the experimental groups. The recovery period in animals in the experimental group was 2-3 days less than in the control.

According to the test results, the proposed drug is applicable for the prevention and adjunctive treatment of the following pathologies: anemia, hypo- and vitamin deficiency, poisoning, pregnancy toxicosis, childbirth, infectious diseases (pneumonia, bronchitis, hepatitis, etc.). Using the drug can reduce postnatal mortality, increase the viability of offspring.

Thus, the claimed method has a noticeable positive therapeutic and prophylactic effect on the animal organism, namely it improves detoxification functions, stimulates the normalization of impaired metabolism, and increases the body's immunity.

Thus, for the proposed drug and its use, a study was made of acute toxicity, the allergenic effect of the drug on laboratory animals, tolerance, subchronic toxicity, as well as effectiveness on pigs, calves and dogs. Studies of the effectiveness of the drug in pigs was carried out in a collective farm. Frunze of the Belgorod region of the Belgorod region and AOZT Siberian of the Tomsk region, on calves - in the conditions of the dairy complex ONO OPKh Belgorodskoye GNU BelNIISKH of the Russian Agricultural Academy, as well as in the SEC Rodina of the Tomsk region of the Tomsk region, on dogs - in the OPKh Central Belgorod region of the Belgorod region. There are acts confirming the effectiveness of the proposed drug.

According to the test results, the proposed drug is applicable for the prevention and adjunctive treatment of the following pathologies: anemia, hypo- and vitamin deficiency, poisoning, pregnancy toxicosis, childbirth, infectious diseases (pneumonia, bronchitis, hepatitis, etc.). Using the drug can reduce postnatal mortality, increase the viability of offspring.

- 8 015078

Table 1

Sows productivity, on average per animal

Indicators Groups 1-control 2-experienced 3 experienced The number of sows, goal eighteen eighteen eighteen Viable piglets born 12.2 ± 0.8 12.9 + 0.5 13.7 + 0.9 Live weight, kg at birth 1.21 + 0.04 1.24 + 0.01 1.28 + 0.07 in% of control - 102,4 105.7 Live weight, kg at weaning 7.33 + 0.80 8.15 + 0.20 8.27 + 0.60 in% of control - 111.1 112.8 The growth for the suction period, kg / goal 6.32 + 0.70 6.53 + 0.90 6.87 + 00.40 Daily average growth g 164.6 + 15.6 178.4 + 17.3 173.9 + 13.7 in% of control - 108.3 105.6 The number of piglets at weaning 9.4 + 0.6 10.8 + 0.7 13.1 + 0.4 Preservation,% 77.0 83.7 95.6

table 2

Hematological blood counts in piglets (at 90 days of age) treated with the proposed drug

Indicators Groups 1-control 2-experienced 3.0ml / 10kg 3 experienced 5.0ml / 10kg Hemoglobin, g / l 105.3 + 3.2 109.8 + 4.1 110.2 + 5.3 Red blood cells, mln / μl 5.12 + 0.15 5.21 + 0.32 5.26 + 0.24 White blood cells, thousand / μl 14.04 + 1.10 13.24 + 1.04 13.02 + 1.40 Total protein, g / l 51.2 + 6.0 52.8 + 2.0 55.1 + 3.0 Albumin,% 37.83 + 2.40 38.14 + 2.10 38.60 + 1.92 a - globulins 23.17 + 2.30 24.07 + 2.41 25.00 + 2.10 β - globulins 20.83 + 2.14 18.87 + 1.99 17.39 + 2.04 γ - globulins 18.17 + 2.04 18.92 + 2.13 19.01 + 2.17 Albumin: Globulins 0.61 + 0.03 0.62 + 0.04 0.63 + 0.03 AsAT, nmol / (h / l) 0.12 + 0.02 0.13 + 0.02 0.14 + 0.02 Al AT, nmol / (h / l) 0.13 + 0.02 0.13 + 0.02 0.14 + 0.02 Calcium, Pol / L 2.75 + 0.15 2.65 + 0.10 2.58 + 0.13 Phosphorus, Paul / L 2.15 + 0.10 2.24 + 0.13 2.41 + 0.10 Zinc, mcg% 10.93 + 0.72 11.97 + 0.40 12.33 + 0.50 Urea, Paul / L 4.40 + 0.47 3.78 + 0.50 3,50 + 0,05 Reserve alkalinity, vol.% CO ₂ 43.36 + 1.12 45.20 + 1.16 49.18 + 1.19 Vitamin A, μg / ml 0.55 + 0.02 0.67 + 0.01 0.88 + 0.04

Table 3

Calf productivity and feed growth costs after 5 days of therapy

Indicators Groups Guy control 2nd experienced (preparation 2.0 ml / 10kg body weight) The average daily gain, g 621.5 + 28.3 653.2 + 34.7 Spent on 1 kg of growth, units 3,7 3,5

- 9 015078

Table 4

Morphological blood counts of calves after 5 days of therapy

Indicators Groups Guy control 2nd experienced (preparation 2.0 ml / 10kg body weight) Red blood cells, mln * μl -1 4.7 ± 0.1 5.2 ± 0.3 White blood cells, thousand "μl -1 7.9 ± 0.6 8.2 ± 0.2 Hemoglobin, * μl -1 7.2 ± 4.2 8.3 ± 2.2

Table 5

Biochemical blood counts of calves after 5 days of therapy

Indicators Groups 1-control 2-experienced Total protein, g / l 64.10 ± 1.51 69.20 ± 3.18 Vitamin A, μg / ml 0.79 ± 0.12 0.93 ± 0.05 R * Λ _rm „tL> /. 1LISHUN1N 1Υ1ΙΧ.1 / o l oo-bp pa η TO4.P Vitamin E, mcg% 0.24 ± 0.02 0.31 ± 0.04 Calcium, mg% 17.30 ± 0.14 18.00 ± 0.15 Phosphorus, mg% 7.20 ± 0.11 6.80 ± 0.12 Zinc, mcg% 178.0 ± 3.9 185.9 ± 1.2

Table 6

The results of therapeutic measures

Group Goal sick Continue treatment duration Goal Recovery Goal Goal The average daily gain, kg Gaya control 10 10 8 2 0.2 2nd experienced 10 5 10 0 0.4

Table 7 Hematological indicators of blood calves ..

Group Hemaglobin Eryth rocy you Lei Kots Ita B E Neutrophils L M M YU P FROM 1 control BEFORE treatment 7.3 4,5 16.1 3.2 0.4 31,2 42 twenty 3,1 After treatment 10,2 5,4 11.8 4.0 4.9 31 54 4,5 2- experienced before treatment 7.3 3.9 16,4 0.1 s, s 0.3 30,0 40 24 2,4 After treatment 11.0 6.9 7.7 0.2 3,1 thirty 63 3.8

- 10 015078

Table 8

Biochemical indicators of blood calves

Group Carotene, mg% Calcium g 1- control 0.250 6.73 0.279 7.05 2- experienced 0.258 6.80 0.282 8.30

Phosphorus, g Res. alkali Total Protein, g% 6.38 36,4 5,6 7.50 33.3 7.2 6.15 35.6 5.5 7.77 33,2 6.8

Sources of scientific and technical information

1. New methods of culture of animal tissues. Ed. Yu.M. Olenova. M., World, 1976.

2. Adams R. Methods of cell cultures for biotechnology. M., World, 1983, 243 p.

3. Demina N.G., Polazhuer B.M., Rumyantseva N.F. Studying the stability of glutamine during its isolation from fermentation processes // Biotechnology. 1992. No. 2, p. 63-67.

4. Infusion therapy and clinical nutrition. Ed. G.N. Khlyabich. Frankfurt am Main.

1992, 796 p.

Claims (6)

CLAIM 1. A preparation for the prevention and correction of pathological conditions of animals, containing the following active substances: B-arginine monohydrochloride in an amount of 48-72 mg / l, B-lysine monohydrochloride in an amount of 48-72 mg / l, B-histidine monohydrochloride in an amount of 13, 8-20.8 mg / l, Bisoleucine in an amount of 13.8-20.8 mg / L, B-leucine in an amount of 41.6-62.4 mg / L, B-methionine in an amount of 10.4-15, 6 mg / l, B-phenylalanine in an amount of 17.2-25.8 mg / l, B-threonine in an amount of 20.8-31.2 mg / l, Briptriptan in an amount of 7.9-10.3 mg / l , B-glutamine in an amount of 68.8-103.2 mg / l, B-valine in an amount of 17.2-25.8 mg / l, B-tyros in in an amount of 27.7-41.5 mg / l, B-cystine monochloride in an amount of 17.9-26.9 mg / l, B-serine in an amount of 17.2-25.8 mg / l, glycine in an amount 34.4-54.6 mg / l, B-a-alanine in an amount of 17.225.8 mg / l, B-proline in an amount of 25.6-38.4 mg / l, B-aspartic acid in an amount of 18.0 -30.0 mg / l, Boxiproline in an amount of 7.9-10.3 mg / L, B-glutamic acid in an amount of 48-72 mg / L, B-cysteine monohydrochloride in an amount of 0.12-0.70 mg / l, choline chloride in an amount of 0.4-3.0 mg / l, folic acid in an amount of 0.01-0.09 mg / l, calcium pantothenate in an amount of 0.01-0.09 mg / l, thiamine hydrochloride in the amount of 0.01-0.09 mg / l, nicot inova acid in an amount of 0.03-0.22 mg / l, pyridoxal monohydrochloride in an amount of 0.03-0.22 mg / l, riboflavin in an amount of 0.012-0.09 mg / l, nicotinamide in an amount of 0.03-0 , 22 mg / l, Ό-biotin in an amount of 0.01-0.09 mg / l, myoinositol in an amount of 0.06-0.45 mg / l, pyridoxine hydrochloride in an amount of 0.03-0.22 mg / l , calciferol in an amount of 0.01-0.09 mg / l, ascorbic acid in an amount of 0.06-0.45 mg / l, para-aminobenzoic acid in an amount of 0.06-0.45 mg / l, glucose in an amount of 800- 1200 mg / l, sodium chloride in an amount of 7.2-8.8 g / l, potassium chloride in an amount of 360-440 mg / l, potassium phosphoric acid odnoz substituted in an amount of 54-66 mg / l, sodium phosphoric acid disubstituted 12-aqueous in an amount of 13.5-16.5 mg / l, calcium chloride 6-aqueous in an amount of 24.8-30.4 mg / l, magnesium 6-aqueous chloride in an amount of 9.9-11.6 mg / l, 7-aqueous magnesium sulfate in an amount of 9.0-11.0 mg / l, 9-aqueous iron nitrate in an amount of 0.65-0.79 mg / l, sodium acetic acid 3 aqueous in an amount of 7.1-8.7 mg / l. 2. A method for the prevention and correction of pathological conditions of animals by injection into the body of an animal preparation in the form of an aqueous solution, characterized in that the preparation according to claim 1 is used as a preparation, which is administered to animals intramuscularly or subcutaneously. 3. The method according to claim 2, characterized in that when a dose of 20 ml is exceeded, it is administered in parts in several places. 4. The method according to claim 2 or 3, characterized in that for prophylactic purposes, the drug according to claim 1 is administered 2 times a week for a month in doses of 1.5-2.0 ml per 10 kg of body weight. 5. The method according to claim 2 or 3, characterized in that for therapeutic purposes, the drug according to claim 1 is administered in a dose of 3.05.0 ml per 10 kg of body weight 2 times a day for 3-5 days. 6. The method according to claim 5, characterized in that during intoxication in connection with poisoning by synthetic and / or food poisons, the drug according to claim 1 is administered in a ten-fold therapeutic dose. Eurasian Patent Organization, EAPO Russia, 109012, Moscow, Maly Cherkassky per., 2